Ocugen is involved with the discovery and development of therapies to cure retinal diseases as well as protect against COVID-19. Core to Ocugen’s approach is delivering innovative options for patients, whether it be for unmet clinical needs or providing choice in the area of vaccines. Using their breakthrough modifier gene therapy platform, Ocugen is advancing vaccine research, as well as gene and cell therapies. Currently, Ocugen has several assets in clinical trials, with their lead cell therapy candidate, Neocart® in Phase 3 clinical trials for the treatment of articular cartilage defects in the knee.

Ocugen

Founded: 2013
Location: Malvern, PA
Employee range: 1-50
Funding: 100-500M

Statistical Programmer

Ocugen

Short description:

Drug notes:

Long description:

Jobs: